This study evaluates whether protein synthesis plays a role in targeting RNA molecules to different subcellular domains within neurons. Transport of newly synthesized RNA (labeled with [3HJuridine) was emined in the presence of the protein synthesis inhibitors puromycin and cycloheximide. In situ hybridization was used to determine whether inhibition of protein synthesis altered the subcellular distribution ofmRNAs. Transport ofrecently synthesized RNA was not disrupted after prolonged exposure to either inhibitor. However, inhibition ofprotein synthesis caused several mRNAs that are normally confined to the cell body to appear in dendrites. The distribution of mRNAs that are normally present in dendrites was unaffected. These findings suggest that protein synthesis is not required to translocate RNA into the dendrites but may play a role in restricting particular mRNAs to the neuronal cell body.
Gene expression in differentiated cells is thought to be regulated in part by the spatial organization of nuclear and cytoplasmic matrices (reviewed in ref. 1) . The cytoarchitecture of nuclear and cytoplasmic networks is critical for replication and transcription of DNA as well as translation of RNA (2) (3) (4) (5) . RNA synthesis occurs in defined domains of the nucleus, and there appears to be a conduit system for exporting newly synthesized RNA to the cytoplasm (6) (7) (8) (9) . Once mRNA emerges in the cytoplasm it is often targeted to a particular subcellular destination prior to translation (10-16), which offers an additional level of regulation over cellular gene expression.
One of the most dramatic examples of selective mRNA localization occurs in neurons. Most neuronal mRNAs are found only in neuronal cell bodies (17, 18) . In contrast, a few RNAs including the mRNAs encoding microtubuleassociated protein 2 (MAP2) and the a subunit of calcium/ calmodulin-dependent protein kinase II and the polymerase III transcript BC1 are found in dendrites at considerable distance from the nucleus (10, 11, (17) (18) (19) (20) . In fact, MAP2 mRNA can be detected >100 ,um away from the cell body in cultured neurons (18) . This differential distribution implies the existence of sorting signals that direct some mRNAs to the dendrites and retain others in the cell body. A mechanism for transporting RNA into dendrites has been demonstrated by pulse-labeling newly synthesized RNA with [3H]uridine and then following the migration of labeled RNA into the dendrites (21, 22) . However, little is known about this transport machinery and the signals it may utilize except that some of the newly synthesized RNA transported to the dendrites is attached to the cytoskeleton (21) .
The process that delivers RNA to dendrites must select for a subpopulation of mRNAs. One means by which the dendritic transport machinery may recognize RNAs targeted for transport is via interaction with nascent polypeptides undergoing synthesis. This notion is based on analogy with the The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. mechanism that targets mRNAs encoding membrane proteins to the rough endoplasmic reticulum. The N-terminal domain of the nascent polypeptide is recognized by a signal recognition particle (reviewed in ref. 23 ). The signal recognition particle prevents translation until the complex docks with an appropriate receptor in the endoplasmic reticulum. In a similar way, nascent peptides could target particular mRNAs to the dendritic transport machinery.
Other studies have considered whether this sort of mechanism operates in other cell types. For example, Sundell and Singer (24) have shown that blocking protein synthesis does not disrupt actin mRNA localization in migrating fibroblasts.
In the present study, we have used a similar approach to determine whether protein synthesis is required for dendritic RNA transport in neurons. (25, 26 with the previous findings of Ch'ih et al. (27, 28) .
To avoid these problems we used an alternative approach that took advantage of the fact that nucleocytoplasmic transport of newly synthesized RNA is blocked at room temperature and can be reinstated when cells are warmed to 37°C (29) . Neurons were pulse-labeled with [3H]uridine (50 ,uCi/ ml) at 25°C for 1 hr. Labeling neurons at room temperature will result in less RNA synthesis than would labeling at 37°C.
Nevertheless, because the same temperature and conditions are used for the control neurons, this should not affect the interpretation of the outcome. After the labeling period, puromycin or cycloheximide plus an excess of unlabeled uridine was added. Neurons were maintained at 25°C for an additional 3 hr to allow maximal inhibition of protein synthesis while retaining the previously labeled RNA in the nucleus. The neurons were then warmed to 37°C and maintained for up to 8 hr. Control neurons were pulse-labeled at 25°C, maintained at 25°C for 3 hr, and then returned to 37°C in the absence of inhibitor for the same chase interval.
Fixation. Neurons were fixed for [10] [11] [12] [13] [14] [15] Fig. 1 A   and B) . Translocation also occurred in neurons treated with cycloheximide or puromycin ( Fig. 1 C and D) . The (Fig. 2 A, D, and G) . However, treatment of neurons with either cycloheximide or puromycin for 20 hr resulted in a profound change in mRNA distribution. mRNAs that are normally restricted to the cell body, including those encoding (Fig. 2 A-C) , tubulin (Fig. 2 D-F) , and actin ( Fig. 2 G-1). (Fig. 2 G-1 ) appeared in the dendrites. In many instances, the label extended over all of the primary dendrites. In some cases, only some of the dendrites were labeled, while in other cases the label still appeared to be restricted to the cell body. After 20 hr of treatment with either puromycin or cycloheximide, MAP2 mRNA was still detectable in cell bodies and dendrites of most neurons (Fig. 3) , but the overall level of labeling appeared to be substantially reduced after inhibitor treatment.
To determine how quickly mRNAs that were normally restricted to the cell body entered the dendrites, the distribution of GAP-43 mRNA was examined 2-24 hr after inhibitor treatment. No dendritic labeling was observed after 2 hr, slight labeling of proximal dendrites was seen after 4 hr, and prominent labeling was visible by 6 hr (Fig. 4) somewhat with time in the inhibitor. When cultures were treated with inhibitors for 6 or 12 hr and then pulse-labeled with [3H]uridine and analyzed by autoradiography, the majority of neurons still incorporated [3H]uridine. Thus, the alteration of mRNA distribution evident after exposure to protein synthesis inhibitors for 6 or 12 hr is not likely to be simply due to a reduction in neuronal viability.
DISCUSSION
The mechanisms that permit neurons to target particular mRNAs to specific subcellular destinations are unknown. The experiments reported here represent an attempt to define some of the properties of the sorting and transport mechanisms. Our results show that translocation of newly synthe- sized RNA into dendrites continues in the presence ofprotein synthesis inhibitors. However, this treatment caused a profound change in the distribution of several mRNAs. After 4-6 hr of exposure to protein synthesis inhibitors, actin, tubulin, and GAP-43 mRNAs, which are normally restricted to the cell body, migrate into the dendrites. The distribution of MAP2 mRNA, which is normally dendritic, is unaffected.
The initial intent ofthis study was to determine whether the targeting and transport of RNAs into dendrites depend on a signal sequence-like mechanism. That assumption that the mechanism of RNA translocation in control and drug-treated neurons is identical. It is conceivable that inhibition of protein synthesis blocks normal dendritic transport but that RNA translocation then occurs via a different process, such as diffusion. In most cells, RNA is attached to the cytoskeleton (4) and is apparently unable to diffuse over significant distances (33) (34) (35) . Puromycin causes release of the nascent polypeptide and dissociation of the polyribosome (36) . In fibroblasts, polyribosome dissociation results in release of a large proportion of the total RNA from the cytoskeleton, although most mRNAs remain anchored (36) . Such an effect could permit the diffusion of newly synthesized non-messenger RNAs, an effect that might resemble normal dendritic RNA transport. If this were the case, cycloheximide, which stabilizes polyribosomes (37) (38) (39) , might be expected to have an effect opposite that of puromycin. Like puromycin, cycloheximide would interfere with a signal sequence-mediated transport but would not be expected to enhance RNA diffusion. In fact, RNA translocation continues normally in the presence of cycloheximide. Given these considerations, and the fact that the rate of RNA translocation is similar in control and inhibitor-treated neurons, it seems most likely that the RNA translocation observed in the presence of protein synthesis inhibitors occurs via the same mechanisms as that in control cells.
The redistribution of those mRNAs normally confined to the cell body that was induced by protein synthesis inhibitors was quite unexpected. This redistribution of mRNA could have occurred in any of at least three different ways. Inhibition of protein synthesis could (i) cause the release of mRNAs that are normally anchored within the cell body, and so are prevented from entering dendrites; (ii) interfere with the selectivity of the dendritic transport machinery so that mRNAs normally restricted to the cell body are mistakenly transported; or (iii) increase the half-life of mRNAs generally, thereby extending the distribution of messages that normally are degraded before they reach the dendrites. Of these possibilities, the last seems the least likely. Cycloheximide treatment is known to stabilize some mRNAs (40, 41) , but puromycin has not been reported to have this effect (41) . Beyond this, a large number of different mRNAs (probably with very different half-lives) are restricted to the cell body; it seems somewhat unlikely that the only mechanism restricting mRNAs to the cell body depends on their having a short half-life. Our results are compatible with either of the other two possibilities.
How might inhibition ofprotein synthesis interfere with the anchoring or targeting of neuronal mRNAs? One possibility is that the restriction of mRNAs to the cell body-but not their transport into the dendrites-depends on a signal sequence mechanism. A related possibility is that mRNAs are retained in the cell body by a number of different translationdependent processes and that all mRNAs that are not being translated are transported. For example, actin and tubulin are assembled into cytoskeletal elements as they are being synthesized (so-called cotranslational assembly; ref. 42) . Both puromycin and cycloheximide could disrupt anchoring based on cotranslational assembly. The mRNAs for membrane proteins would presumably be anchored to the endoplasmic reticulum via a signal sequence mechanism (which would be disrupted by the inhibitors). And mRNAs for other proteins (like GAP-43) might be anchored by other translationdependent processes.
A final possibility is that a relatively short-lived protein(s) plays a role in anchoring somatic mRNAs or preventing them from interacting with the dendritic transport machinery. Prolonged inhibition of protein synthesis may result in turnover of these proteins and consequent redistribution of mRNAs.
Regardless of the mechanisms that cause the mRNAs encoding actin, tubulin, and GAP-43 to move into dendrites after protein synthesis inhibition, it is significant that they are able to leave the cell body at all. In the past, selective transport and targeting of RNA in neurons have been considered primarily in terms of how particular mRNAs are targeted to and translocated within dendrites (21, 22, 43) . The present results suggest that the cellular mechanisms responsible for restricting particular mRNAs to the cell body may be as important for mRNA compartmentation in neurons as the mechanisms responsible for the selective delivery of mRNAs into dendrites.
